Loading
A phase 2 trial of toripalimab in triple-negative breast cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.
Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07457359 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 18 participants, started 2026-01-04 and due to reach its primary completion in 2028-01-04. Interventions recorded: SBRT; Toripalimab (anti-PD-1 antibody); Chemotherapy switch. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Histologically confirmed triple-negative phenotype: ER \< 1 %, PR \< 1 % by IHC, HER2 negative (IHC 0/1+ or IHC 2+ with ISH negative)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.